Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $58.11 Consensus Target Price from Brokerages

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) have received an average rating of “Buy” from the fourteen brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eleven have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $58.1111.

A number of brokerages have recently issued reports on TERN. Barclays upped their price target on Terns Pharmaceuticals from $36.00 to $56.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. TD Cowen raised Terns Pharmaceuticals to a “strong-buy” rating in a research report on Friday, February 20th. HC Wainwright upped their target price on shares of Terns Pharmaceuticals from $20.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. BMO Capital Markets raised their price target on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Finally, Truist Financial lifted their price target on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th.

Insider Buying and Selling at Terns Pharmaceuticals

In related news, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the sale, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Amy L. Burroughs sold 71,339 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $38.10, for a total value of $2,718,015.90. Following the completion of the transaction, the chief executive officer directly owned 138,976 shares in the company, valued at approximately $5,294,985.60. This represents a 33.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 170,409 shares of company stock worth $6,563,769 over the last three months. Insiders own 1.50% of the company’s stock.

Institutional Trading of Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TERN. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Terns Pharmaceuticals in the fourth quarter worth about $25,000. GAMMA Investing LLC grew its stake in shares of Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after acquiring an additional 770 shares during the period. iA Global Asset Management Inc. purchased a new stake in Terns Pharmaceuticals in the 4th quarter worth approximately $43,000. FNY Investment Advisers LLC bought a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $80,000. Finally, EverSource Wealth Advisors LLC raised its stake in Terns Pharmaceuticals by 61.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,207 shares of the company’s stock worth $89,000 after acquiring an additional 841 shares during the period. 98.26% of the stock is owned by hedge funds and other institutional investors.

Terns Pharmaceuticals Trading Up 2.8%

TERN stock opened at $47.78 on Monday. The stock has a market capitalization of $4.96 billion, a PE ratio of -46.39 and a beta of -0.31. The stock’s 50 day simple moving average is $39.21 and its 200 day simple moving average is $27.08. Terns Pharmaceuticals has a 12-month low of $1.87 and a 12-month high of $48.26.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.